Key result
Pegylated liposomal doxorubicin linked to ~48% lower disease recurrence risk versus epirubicin in breast cancer.
Why the study?
The short-term outcomes, prognosis, and cardiac safety of pegylated liposomal doxorubicin-based neoadjuvant chemotherapy compared to epirubicin-based therapy in breast cancer remained to be evaluated.
Does Pegylated Liposomal Doxorubicin-based neoadjuvant chemotherapy improve overall and disease-free survival compared to epirubicin-based therapy in patients with stage II-III breast cancer?
Cohort (n=304)
No
Does Pegylated Liposomal Doxorubicin-based neoadjuvant chemotherapy improve overall and disease-free survival compared to epirubicin-based therapy in patients with stage II-III breast cancer?
PLD-based neoadjuvant chemotherapy significantly improves disease-free and overall survival compared to epirubicin in stage II-III breast cancer, without increasing cardiotoxicity.
Answers are grounded in this paper and cite their sources.
May support PLD preference in neoadjuvant breast cancer; hypothesis-generating pending randomized confirmation.
Purpose This study aims to evaluate the short-term outcomes and prognosis and the cardiac safety of PLD-based neoadjuvant chemotherapy (NAC) compared to epirubicin-based therapy in breast cancer treatment. Methods 304 patients diagnosed with stages II and III breast cancer were enrolled including 97 cases treated with PLD and 207 controls treated with epirubicin in neoadjuvant chemotherapy. The effectiveness of the anti-breast cancer treatment was evaluated using overall survival (OS) and disease-free survival (DFS) metrics, while cardiac toxicity was measured through the left ventricular ejection fraction (LVEF) and electrocardiogram (ECG) assessments. Results The 5-year DFS and OS rates in the PLD group were 84.5% and 88.7% (with 15 recurrences and 11 deaths), while in the control group, these rates were 72.9% and 79.2% (with 56 recurrences and 43 deaths). Regarding cardiac toxicity, there was no significant difference in ECG abnormalities or left ventricular ejection fraction (LVEF) decline between the two groups. Conclusion The study suggests that PLD-based neoadjuvant chemotherapy may provide substantial benefits in terms of DFS and OS, along with a safe cardiac toxicity profile, in patients with stage II-III breast cancer.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) conducted a cohort in Stages II and III breast cancer (n=304). Pegylated Liposomal Doxorubicin (PLD) vs. Epirubicin was evaluated on 5-year Disease-Free Survival (DFS) (HR 0.52, 95% CI 0.30-0.92, p=0.0227). Pegylated liposomal doxorubicin-based neoadjuvant chemotherapy reduced the risk of disease recurrence by 48% compared to epirubicin-based therapy in patients with stage II-III breast cancer.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: